Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Assets (2016 - 2025)

United Therapeutics' Other Non-Current Assets history spans 17 years, with the latest figure at $196.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 11.35% year-over-year to $196.9 million; the TTM value through Dec 2025 reached $196.9 million, down 11.35%, while the annual FY2025 figure was $196.9 million, 11.35% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $196.9 million at United Therapeutics, down from $262.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $262.6 million in Q3 2025 and bottomed at $105.8 million in Q2 2022.
  • The 5-year median for Other Non-Current Assets is $159.8 million (2023), against an average of $161.2 million.
  • The largest annual shift saw Other Non-Current Assets tumbled 40.23% in 2022 before it soared 46.31% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $108.2 million in 2021, then increased by 5.64% to $114.3 million in 2022, then skyrocketed by 32.81% to $151.8 million in 2023, then skyrocketed by 46.31% to $222.1 million in 2024, then dropped by 11.35% to $196.9 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Other Non-Current Assets are $196.9 million (Q4 2025), $262.6 million (Q3 2025), and $233.3 million (Q2 2025).